|
|
|
|
Дата |
|---|
| 16.09.2026 |
| 15.09.2026 |
| 14.09.2026 |
| 13.09.2026 |
| 10.09.2026 |
| 09.09.2026 |
| 08.09.2026 |
| 07.09.2026 |
| 06.09.2026 |
| 03.09.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
|
|
117.77
|
117.50
|
124.00
|
117.80
|
|
|
114 476 539.68
|
2 770.00
|
|
|
|
119.00
|
117.01
|
120.50
|
117.77
|
|
|
66 239 182.54
|
2 043.00
|
|
|
|
125.11
|
118.16
|
125.90
|
119.00
|
|
|
109 775 783.59
|
3 716.00
|
|
|
|
126.79
|
125.11
|
127.75
|
125.11
|
|
|
42 043 668.83
|
1 784.00
|
|
|
|
127.20
|
125.54
|
128.66
|
126.79
|
|
|
51 111 656.37
|
2 066.00
|
|
|
|
128.48
|
127.07
|
129.69
|
127.20
|
|
|
52 884 946.48
|
1 675.00
|
|
|
|
127.85
|
128.05
|
132.85
|
128.48
|
|
|
112 217 095.36
|
2 835.00
|
|
|
|
128.00
|
127.85
|
129.60
|
127.85
|
|
|
59 710 268.54
|
1 686.00
|
|
|
|
129.70
|
127.76
|
130.40
|
128.00
|
|
|
81 517 476.37
|
2 454.00
|
|
|
|
126.00
|
126.64
|
133.00
|
129.70
|
|
|
194 895 761.98
|
4 107.00
|
Период |
|---|
| 2025, регулярные |
| 2022, регулярные |
| 2020, регулярные |
| 2018, регулярные |
| 2017, регулярные |
| 2016, регулярные |
| 2015, регулярные |
| 2012, регулярные |
| 2011, регулярные |
| 2010, регулярные |
|
Экс-дивидендная дата
|
Закрытие реестра |
Сумма выплаты |
|---|---|---|
|
26.04.2026
|
27.04.2026 |
3.5 EGP |
|
13.04.2023
|
18.04.2023 |
2 EGP |
|
21.04.2021
|
25.04.2021 |
2.95 EGP |
|
02.05.2019
|
05.05.2019 |
4 EGP |
|
06.04.2018
|
10.04.2018 |
4.5 EGP |
|
08.05.2017
|
09.05.2017 |
3.5 EGP |
|
21.04.2016
|
24.04.2016 |
3.5 EGP |
|
23.04.2013
|
24.04.2013 |
3 EGP |
|
24.05.2012
|
27.05.2012 |
3 EGP |
|
29.04.2011
|
02.05.2011 |
2.5 EGP |
Egyptian International Pharmaceuticals Industries Co SAE (EIPICO) is an Egypt-based public shareholding company that operates in the pharmaceuticals industry. The Company is a manufacturer and exporter of pharmaceuticals, and holds license agreements with a group of international pharmaceutical companies to produce their products locally and replace the imported ones. The Company produces dosage forms, such as spansule capsules (long-acting), as well as non-traditional dosage forms, such as the soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets
